Patents by Inventor Jane Guo Shiah

Jane Guo Shiah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 10076492
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 18, 2018
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Sustained drug delivery implant
    Patent number: 9610246
    Abstract: Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: April 4, 2017
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Chetan Pujara
  • SUSTAINED DRUG DELIVERY IMPLANT
    Publication number: 20170056399
    Abstract: Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
    Type: Application
    Filed: November 14, 2016
    Publication date: March 2, 2017
    Inventors: Jane-Guo Shiah, Chetan Pujara
  • BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS
    Publication number: 20160199297
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.
    Type: Application
    Filed: January 11, 2016
    Publication date: July 14, 2016
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCES
    Publication number: 20160074418
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Application
    Filed: November 23, 2015
    Publication date: March 17, 2016
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 9233070
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: January 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Ocular implant made by a double extrusion process
    Patent number: 9192511
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: November 24, 2015
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • EXTENDED RELEASE BIODEGRADABLE OCULAR IMPLANTS
    Publication number: 20150209276
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
    Type: Application
    Filed: January 30, 2015
    Publication date: July 30, 2015
    Applicant: Allergan, Inc.
    Inventors: Thierry Nivaggioli, James Jane-Guo Shiah, Qing Lin
  • METHODS OF TREATMENT OF OCULAR CONDITIONS WITH A SUSTAINED DRUG DELIVERY IMPLANT
    Publication number: 20150140062
    Abstract: Intraocular implants may include a corticosteroid and a biodegradable polymer associated with the corticosteroid to facilitate the release of the corticosteroid into an eye for a period of time. In some embodiments, ocular conditions, such as diabetic macular edema can be treated through administration of an intraocular implant including a corticosteroid and a biodegradable polymer associated with the corticosteroid to the eye of a human at a frequency of about once every six months to about once a year.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Extended release biodegradable ocular implants
    Patent number: 8974812
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: March 10, 2015
    Assignee: Allergan, Inc.
    Inventors: Thierry Nivaggioli, Jane-Guo Shiah, Qing Lin
  • Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
    Patent number: 8968766
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Joan-En Lin, Jane-Guo Shiah, Thierry Nivaggioli
  • Extended release biodegradable ocular implants
    Patent number: 8895049
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 25, 2014
    Assignee: Allergan, Inc.
    Inventors: Thierry Nivaggioli, Jane Guo Shiah, Qing Lin
  • EXTENDED RELEASE BIODEGRADABLE OCULAR IMPLANTS
    Publication number: 20140249123
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
    Type: Application
    Filed: February 26, 2014
    Publication date: September 4, 2014
    Applicant: Allergan, Inc.
    Inventors: Thierry Nivaggioli, Jane-Guo Shiah, Qing Lin
  • SUSTAINED DRUG DELIVERY IMPLANT
    Publication number: 20140234390
    Abstract: Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
    Type: Application
    Filed: March 18, 2014
    Publication date: August 21, 2014
    Applicant: ALLERGAN, INC.
    Inventors: Jane-Guo Shiah, Chetan Pujara
  • SUSTAINED DRUG DELIVERY IMPLANT
    Publication number: 20140234389
    Abstract: Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
    Type: Application
    Filed: February 14, 2014
    Publication date: August 21, 2014
    Applicant: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Chetan Pujara
  • Ocular implant made by a double extrusion process
    Patent number: 8778381
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 15, 2014
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Extended release biodegradable ocular implants
    Patent number: 8685435
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: April 1, 2014
    Assignee: Allergan, Inc.
    Inventors: Thierry Nivaggioli, Jane Guo Shiah, Qing Lin
  • EXTENDED RELEASE BIODEGRADABLE OCULAR IMPLANTS
    Publication number: 20140035184
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
    Type: Application
    Filed: October 8, 2013
    Publication date: February 6, 2014
    Inventors: Thierry Nivaggioli, Jane Guo Shiah, Qing Lin
  • Biodegradable Intravitreal Tyrosine Kinase Implants
    Publication number: 20140031408
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Application
    Filed: August 19, 2013
    Publication date: January 30, 2014
    Applicant: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCES
    Publication number: 20130295157
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Application
    Filed: June 20, 2013
    Publication date: November 7, 2013
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber